🆕 2026 ACC/AHA Clinical Performance & Quality Measures for Patients With #cvPAD, released in collab w/ nine other specialty societies, offer a comprehensive framework to assess & elevate PAD care across clinical settings.
Read more: https://bit.ly/3YPxPrD #JACC #CardioSky #MedSky
The new 2026 ACC/AHA/Multisociety Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease (PAD) provide a comprehensive framework for assessing and improving PAD care across various clinical settings.
Get the details in #JACC: https://bit.ly/45xtCMK #cvPAD #CardioSky
A 🆕 ACC Scientific Statement on the management of #cvPAD in adults w/ diabetes adds context to the 2024 ACC/AHA Lower Extremity PAD Guideline & "emphasizes a modern, evidence-based approach to care" starting w/ screening & advancing through treatment.
More: 🔗 https://bit.ly/3YxYJDU #CardioSky
New ACC Scientific Statement on the management of PAD in adults w/ #diabetes adds context to the 2024 ACC/AHA Lower Extremity PAD Guideline & "emphasizes a modern, evidence-based approach to care" starting w/ screening & advancing through treatment. https://bit.ly/4596FiD
#JACC #CardioSky #cvPAD
#FusterCVS 2025 Day 1️⃣ is over! Thank you to all who participated in today's sessions covering a range of topics from evolving new frontiers in arterial disease to trends & challenges of approaching prevention.
Plan your Day 2️⃣ here and learn more about the symposium 👉 https://bit.ly/44UrPky #cvPAD
In a STRIDE post-hoc analysis, #semaglutide 1.0 mg improved functional outcomes in early symptomatic #cvPAD + #T2D regardless of sex. Baseline differences in females underscore the need for sex-specific evaluation in PAD trials. https://bit.ly/4fWwsik
#JACC #ESCCongress #WCCardio #QoL
The STRIDE trial demonstrated that semaglutide significantly improves function, symptoms, and health-related QoL in patients with symptomatic #cvPAD and T2DM.
Get the full clinical trial details here ➡️ bit.ly/42dnA1n #ACC25 #CardioSky #MedSky
💡 #Semaglutide is the first therapy to ⬇️ #MACE, improve cardiometabolic and kidney outcomes and improves walking capacity, symptoms, and related #QoL in patients with #cvPAD and #T2D
#ACC25 #JACCJournals #CardioSky
#Semaglutide:
🔹 Significantly improved function and met criteria for a clinically meaningful change
🔹Significantly improved symptoms and quality of life
🔹Reduced disease progression
🔹Improved ABl
🔹Safety consistent with previous trials with no unexpected safety findings
#ACC25 #CardioSky #cvPAD
Dr. Marc Bonaca on the effect of once-weekly subcutaneous #semaglutide on functional capacity in people with #T2D and #cvPAD
#ACC25 #JACCJournals
